Programme
2026 GMFH Summit
All times are in local time CET
Diet and other ways to manipulate the gut Microbiome in clinical practice
Saturday, March 14
8:15 – 8:30
Welcome and Day 1 Kickoff
Harry Sokol (France)
Giovanni Barbara (Italy)
Keynote Lecture:
8:30 – 9:00
Objective assessment of dietary intake: present and future
Lawrence David (USA)
PLENARY SESSION 1:
Diet as a major actor in shaping the microbiome
Session Moderator: Nicola Segata (Italy)
9:00 – 9:30
Critical reflection of ultra-processed foods
Ciarán Forde (Netherlands)
9:30 – 10:00
Are fibers always beneficial?
Heather Armstrong (Canada)
10:00 – 10:30
Role of the microbiome in the personalized response to diet
Eran Segal (Israel)
10:30 – 11:00
Morning Break
PLENARY SESSION 2:
New links between diet, gut microbiota and health
Session Moderator: Heather Armstrong (Canada)
11:00 – 11:30
Microbiome-dependant benefit of a non-industrialized-type diet on cardiometabolic outcomes
Jens Walter (Ireland)
11:30 – 12:00
Intestinal Blastocystis and cardiometabolic outcomes
Francesco Asnicar (Italy)
12:00 – 12:30
Diet signatures in the gut microbiome and associated health outcomes
Nicola Segata (Italy)
12:30 – 14:00
Lunch
WORKSHOP SESSIONS
Note: Two sessions are held concurrently and are not repeated.
14:00 – 15:30
WORKSHOPS 1 and 2
1. Diet in IBD: What should I tell my patients? (lessons from ECCO consensus)
Moderator: Jens Walter (Ireland)
Diet in disease prevention
Richard Hansen (UK)
Diet in the treatment of IBD
Chen Sarbagilli Shabat (Israel)
2. Diet in Liver diseases: What should I tell my patients?
Moderator: Max Nieuwdorp (Netherlands)
Metabolic control of liver cancer
Mathias Heikenwälder (Germany)
Diet in the prevention and treatment of Liver diseases
Gabriel Perlemuter (France)
15:30 – 16:00
Afternoon Break
16:00 – 17:30 pm
WORKSHOPS 3 and 4
3. Diet in IBS: What should I tell my patients?
Moderator: Giovanni Barbara (Italy)
Diet-microbiome interaction in IBS (focus on pathogenesis)
Magnus Simren (Sweden)
Role of diet in the treatment of IBS (focus on practical use of diet in treatment of IBS)
Miranda Lomer (UK)
4. Diet in cancer: What should I tell my patients?
Moderator: Lisa Derosa (France)
Role of Diet in carcinogenesis
Wendy Garrett (USA)
Diet as an adjuvant to therapy
Robert Jenq (USA)
Sunday, March 15
08:15 – 08:20
Kickoff
Gail Hecht (USA)
PLENARY SESSION 3:
Clinical stage Microbiome-derived treatments
Session Moderator: Harry Sokol (France)
08:20 – 08:50
Gut microbiota-derived treatments in metabolic syndrome
Max Nieuwdorp (Netherlands)
08:50 – 09:20
New LBP in the treatment of Clostridioides difficile infection
Nicolas Benech (France)
09:20 – 09:50
Microbiota-targeted approaches in IBS
Purna Kashyap (USA)
09:50 – 10:20
Update on the role of gut fecal microbiota transplant in IBD and IBS
Simon Mark Dahl Baunwall (Denmark)
10:20 – 10:50
Morning Break
PLENARY SESSION 4:
Microbiome Therapeutics in Cancer
Session Moderator: Robert Jenq (USA)
10:50 – 11:20
FMT to boost response to immune checkpoint inhibitors
Gianluca Ianiro (Italy)
11:20 – 11:50
Targeting the microbiome in cancer: The Oncobiome project
Lisa Derosa (France)
11:50 – 12:20
LBP to boost response to immune checkpoint inhibitors in metastatic renal cell carcinoma
Miguel Zugman (USA)
12:20 – 12:30
Closing remarks
Harry Sokol (France), Gail Hecht (USA)
